Finance

Lists
SMMT:NASDAQ
Summit Therapeutics Inc
$13.66
-8.81%
(-1.32) 1D
Jul 24, 4:00:00 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for SMMT...
Open
$13.72
High
$14.42
Low
$13.20
Mkt. cap
10.90B
Avg. vol.
5.07M
Volume
8.15M
52-wk high
$30.98
52-wk low
$12.55
EPS
-$1.60
Beta
-1.26
Shares outstanding
776.16M
No. of employees
265
Open
$13.72
High
$14.42
Low
$13.20
Mkt. cap
10.90B
Avg. vol.
5.07M
Volume
8.15M
52-wk high
$30.98
52-wk low
$12.55
EPS
-$1.60
Beta
-1.26
Shares outstanding
776.16M
No. of employees
265
News stories
From sources across the web
About Summit Therapeutics Inc
CEORobert Duggan | Maky Zanganeh
Employees265
Founded2003
Headquarters-
SectorBiotechnology
Websitesmmttx.com
Analyst ratings
Based on 13 analysts giving stock ratings to SMMT in the past 3 months
Buy
Buy
8
Hold
4
Sell
1
12-month forecast
Based on 13 Wall Street analysts offering 12 month price targets for SMMT in the last 3 months.
Highest
Current $13.66
$41.00 (+200.15%)
Average
$28.25 (+106.81%)
Lowest
$9.80 (-28.26%)
Analyst
Recommendation
Action
Price target
Projected
Date
Faisal Khurshid
Jefferies
Hold
Maintained
$15.00
+9.8%
07/24/2026
Dara Azar
Stifel Nicolaus
Buy
Reiterated
$38.00
+178.2%
07/25/2026
Kelsey Goodwin
Piper Sandler
Hold
Maintained
$16.00
+17.1%
07/24/2026
Bradley Canino
Guggenheim
Buy
Reiterated
$38.00
+178.2%
07/23/2026
Mitchell Kapoor
H.C. Wainwright
Hold
Reiterated
-
-
07/24/2026
Yigal Nochomovitz
Citi
Buy
Reiterated
$40.00
+192.8%
07/24/2026
Etzer Darout
Barclays
Hold
Maintained
$18.00
+31.8%
07/23/2026
Salveen Richter
Goldman Sachs
Buy
Maintained
$41.00
+200.1%
07/20/2026
Jeffrey Walch
Bernstein
Sell
Reiterated
$9.80
-28.3%
06/21/2026
Mohit Bansal
Wells Fargo
Buy
Reiterated
$30.00
+119.6%
06/02/2026
Unknown Analyst
Bernstein
Sell
Initiated
$7.70
-43.6%
05/21/2026
Tyler Van Buren
TD Cowen
Buy
Maintained
-
-
05/06/2026
Cory Kasimov
Evercore ISI
Buy
Maintained
$34.00
+148.9%
05/01/2026
William Maughan
Clear Street
Buy
Maintained
$31.00
+126.9%
05/01/2026
Stephen Willey
Stifel Nicolaus
Buy
Initiated
$45.00
+229.4%
04/08/2026
Asthika Goonewardene
Truist Financial
Buy
Reiterated
$35.00
+156.2%
02/24/2026
Previous reportsAll values in GBP
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
131.10M
147.29M
132.62M
157.73M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
103.12M
77.63M
62.59M
62.76M
Operating expense
234.21M
224.92M
195.21M
220.50M
Total operating expenses
234.21M
224.92M
195.21M
220.50M
Operating income
-234.21M
-224.92M
-195.21M
-220.50M
Other non operating income
-
-
-
500.00K
EBT including unusual items
-231.79M
-219.17M
-189.42M
-215.70M
EBT excluding unusual items
-231.79M
-219.17M
-189.42M
-215.70M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-231.79M
-219.17M
-189.42M
-215.70M
Net profit margin
-
-
-
-
Earnings per share
-
-
-
-
Interest and investment income
2.78M
5.88M
5.85M
4.39M
Interest expense
-
-
-
-
Net interest expenses
2.78M
5.88M
5.85M
4.39M
Depreciation and amortization charges
-
-
-
-
EBITDA
-234.17M
-224.88M
-195.17M
-220.45M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

What's on your mind?
What's going on with the markets today?
Explore what’s possible
Create a portfolio
Create a task
Deep Search
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer